Seeking Alpha

Robert Schwartz  

Dr. Schwartz is a 30-year veteran of the Pharmaceutical Industry most recently in the role of Executive Director, Strategic Transactions for Bristol-Myers Squibb Company where he has more than a dozen completed transactions to his credit. He speaks frequently on the Biotech-Big Pharma dynamics and evolving research and treatment paradigms in oncology and is perhaps best known for predicting FDA’s rejection of Dendreon’s Provenge vaccine in 2007 (San Francisco Chronicle, March 30, 2007). Provenge ultimately won FDA approval in April, 2010.

Dr. Schwartz founded RHS Advisors, LLC, a life-sciences consulting firm, in July 2010.
  • Description: Company executive. Trading frequency: Weekly
  • Interests: Options, Stocks - long, Stocks - short, Tech stocks
RHS Advisors, LLC We are a Life-sciences consulting firm serving the Pharmaceutical, Biotechnology and Investment communities. Our team has extensive broad-based Big Pharma experience in drug development and licensing. We offer a range of services to the Pharmaceutical, Biotechnology and Investment communities including: - ...More
Long & Short Our credibility is critical to the sustainability of our business. We will never write about or otherwise provide commentary on companies that are the subject of ongoing research efforts or for which we or our clients have established positions.That said, we are currently long: BIIB, CELG, CLDX, GILD, ILMN, ...More
Currently, you have no book details. Click edit to add book details.
$AVEO Why AVEO Pharmaceuticals' Tivozanib Will Be Approved For The Treatment of Advanced Renal Cell Carcinoma Mar 20, 2013